Description
Developer and researcher of biopharmaceuticals for molecular nuclear oncology. The company specializes in developing innovative biological drug products including both diagnostics and therapeutics formulations targeting molecular oncology, providing reliable and effective products for better cancer treatment.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Later Stage VC (Series C) | 05-Jul-2021 | $15.5M | 000.00 | Completed | Generating Revenue | |
3. Early Stage VC (Series B) | 23-Apr-2020 | 000.00 | 000.00 | Completed | Generating Revenue | |
2. Early Stage VC | 08-Mar-2018 | Completed | Startup | |||
1. Seed Round | 21-Mar-2016 | Completed | Startup |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Tao Xu | Chief Executive Officer |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
ABCI Securities | Investment Bank | Minority | 000 0000 | 000000 0 | |
Ciit Asset Management | Asset Manager | Minority | 000 0000 | 000000 0 | |
Qirong Venture Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Tasly Capital | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Furong Capital | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |